The Myeloproliferative Neoplasms Channel on VJHemOnc is an independent medical education platform, supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
Texas MPN Workshop 2022 | Parsaclisib plus ruxolitinib in myelofibrosis: a promising strategy for treatment-naive patients
Abdulraheem Yacoub, MD, The University of Kansas, Westwood, KS, discusses the potential addition of parsaclisib to ruxolitinib for the treatment of patients with myelofibrosis (MF). Dr Yacoub first highlights the promising activity that has been observed with the use of parsaclisib, and then gives an overview of clinical trials investigating this combination. This interview took place at the third annual Texas MPN Workshop (TMW) 2022, held in San Antonio, TX.
